Tumour lysis syndrome: new therapeutic strategies and classificationCAIRO, Mitchell S; BISHOP, Michael.British journal of haematology. 2004, Vol 127, Num 1, pp 3-11, issn 0007-1048, 9 p.Article

Rasburicase for the treatment and prevention of hyperuricemiaYIM, Barbara T; SIMS-MCCALLUM, Rosalyn P; CHONG, Pang H et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 7-8, pp 1047-1054, issn 1060-0280, 8 p.Article

A review of tumour lysis syndrome with targeted therapies and the role of rasburicaseBOSE, P; QUBAIAH, O.Journal of clinical pharmacy and therapeutics (Print). 2011, Vol 36, Num 3, pp 299-326, issn 0269-4727, 28 p.Article

Stabilization of rasburicase and physico-chemical characterization of the resulting injectable formulationBAYOL, Alain; BREUL, Thierry; DUPIN, Patrice et al.Drug development and industrial pharmacy. 2004, Vol 30, Num 8, pp 877-889, issn 0363-9045, 13 p.Article

Clarifying the role of rasburicase in tumor lysis syndromeSOOD, Amy R; BURRY, Lisa D; CHENG, Doret K. E et al.Pharmacotherapy. 2007, Vol 27, Num 1, pp 111-121, issn 0277-0008, 11 p.Article

Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancyHUTCHERSON, Donald A; GAMMON, David C; BHATT, Mansi S et al.Pharmacotherapy. 2006, Vol 26, Num 2, pp 242-247, issn 0277-0008, 6 p.Article

Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignanciesTRIFILIO, S. M; PI, J; ZOOK, J et al.Bone marrow transplantation (Basingstoke). 2011, Vol 46, Num 6, pp 800-805, issn 0268-3369, 6 p.Article

Safety and efficacy of rasburicase (SR29142) in a Japanese phase II studyISHIZAWA, Kenichi; OGURA, Michinori; HAMAGUCHI, Motohiro et al.Cancer science. 2009, Vol 100, Num 2, pp 357-362, issn 1347-9032, 6 p.Article

Perspectives des uricases dans la goutteGARAY, Ricardo P; EL-GEWELY, Raafat; LABAUNE, Jean-Pierre et al.Revue du rhumatisme (Ed. française). 2012, Vol 79, Num 1, pp 17-22, issn 1169-8330, 6 p.Article

Single-dose rasburicase for tumour lysis syndrome in adults : weight-based approachCAMPARA, M; SHORD, S. S; HAAF, C. M et al.Journal of clinical pharmacy and therapeutics (Print). 2009, Vol 34, Num 2, pp 207-213, issn 0269-4727, 7 p.Article

Actualités sur le traitement du syndrome de lyse tumorale Place de la rasburicase (Fasturtec®)URBIETA, M.Archives de pédiatrie (Paris). 2005, Vol 12, pp 8-12, issn 0929-693X, 5 p., HS1Article

Effect of elevated serum uric acid on cisplatin-induced acute renal failureRONCAL, Carlos A; WEI MU; CROKER, Byron et al.American journal of physiology. Renal physiology. 2007, Vol 61, Num 1, issn 1931-857X, F116-F122Article

Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adultsMCDONNELL, Anne M; LENZ, Kristi L; FREI-LAHR, Debra A et al.Pharmacotherapy. 2006, Vol 26, Num 6, pp 806-812, issn 0277-0008, 7 p.Article

Hemolysis and methemoglobinemia secondary to rasburicase administrationBROWNING, Linda A; KRUSE, James A.The Annals of pharmacotherapy. 2005, Vol 39, Num 11, pp 1932-1935, issn 1060-0280, 4 p.Article

Fixed-Dose Rasburicase in Overweight and Obese Patients Versus Normal-Weight PatientsCLEMMONS, Amber B; ENSLEY, Elizabeth; HOGE, Stephanie et al.The Annals of pharmacotherapy. 2014, Vol 48, Num 9, pp 1152-1158, issn 1060-0280, 7 p.Article

Consensus conference on the management of tumor lysis syndromeTOSI, Patrizia; BAROSI, Giovanni; TURA, Sante et al.Haematologica (Roma). 2008, Vol 93, Num 12, pp 1877-1885, issn 0390-6078, 9 p.Article

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemiaTRIFILIO, S; GORDON, L; SINGHAL, S et al.Bone marrow transplantation (Basingstoke). 2006, Vol 37, Num 11, pp 997-1001, issn 0268-3369, 5 p.Article

Efficacy and (Pharmaco)Kinetics of One Single Dose of Rasburicase in Patients with Chronic Kidney DiseaseSESTIGIANI, E; MANDREOLI, M; GUARDIGLI, M et al.The Nephron journals. 2008, Vol 108, Num 4, issn 1660-8151, c265-c271Article

Rasburicase : A review of its use in the management of anticancer therapy-induced hyperuricaemiaOLDFIELD, Vicki; PERRY, Caroline M.Drugs (Basel). 2006, Vol 66, Num 4, pp 529-545, issn 0012-6667, 17 p.Article

Rasburicase (Fasturtec - F, CH, B) pour l'hyperuricémie = Rasburicase (fasturtec - F ,CH ,B) for hyperuricemiaThe Medical letter on drugs and therapeutics (Edition française). 2002, Vol 24, Num 25, pp 106-107, issn 0253-8512, 2 p.Article

Treatment of Burkitt lymphom in adultsGERECITANO, John; STRAUS, David J.Expert review of anticancer therapy. 2006, Vol 6, Num 3, pp 373-381, issn 1473-7140, 9 p.Article

Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysisFENG, X; DONG, K; PENCE, S et al.Journal of clinical pharmacy and therapeutics (Print). 2013, Vol 38, Num 4, pp 301-308, issn 0269-4727, 8 p.Article

Les traitements de la goutte Molécules actuelles et à venir = Advances in gout therapyCHALES, Gérard; GUGGENBUHL, Pascal.Rhumatos. 2010, Vol 7, Num 57, issn 1771-0081, 126-132 [6 p.]Article

Rasburicase : A new approach for preventing and/or treating tumor lysis syndrome : Biochemical and clinical relevance of hyperuricaemiaBESSMERTNY, Olga; ROBITAILLE, Lauren M; CAIRO, Mitchell S et al.Current pharmaceutical design. 2005, Vol 11, Num 32, pp 4177-4185, issn 1381-6128, 9 p.Article

Mortality Following Rasburicase-Induced MethemoglobinemiaBUCKLIN, Mason H; GROTH, Christine M.The Annals of pharmacotherapy. 2013, Vol 47, Num 10, pp 1353-1358, issn 1060-0280, 6 p.Article